摘要:
There is described a pharmaceutical composition containing a biologically active substance selected from a basic peptide, protein, salt thereof and derivative thereof as well as a fat emulsion as a carrier of the biological active substance. The composition shows an increased biological activity, improved stability to a peptidase, and extended duration in pharmacological effect of the peptide, in comparison with an aqueous solution of the peptide.
摘要:
A readily absorbable motilin preparation contains a motilin-like active substance and a surface active agent. The preferred active substance is L-leucine-13-motilin-homoserine, and the surface active agent is selected from bile salts, saponins and polyethylene glycol higher-alcohol ethers for preparations for nasal administration, and is a peptide lytic enzyme inhibitor for preparations for oral administration.
摘要:
An aqueous solution of motilin, having a pH value adjusted to 4.0 to 5.5 by a pharmaceutically acceptable pH regulator, and lyophilized motilin prepared by freeze-drying said solution.
摘要:
A mucosal absorption-enhancing agent is provided that enables oral, nasal or pulmonary administration of peptide drugs whose administration route has heretofore been limited to the injections due to their poor absorption from the mucosa. Specifically, the mucosal absorption of peptide drugs via intestinal, pulmonary or nasal route can be enhanced by allowing the peptide drugs with the C-terminal fragment (C-CPE) of an enterotoxin (CPE) produced by the bacterium Clostridium perfringens of the genus Clostridium, in particular with the C-CPE or its mutants resulting from the substitution and/or deletion of one or several amino acid residues of the C-CPE to act thereon. The composition for mucosal administration of the present invention significantly enhances absorption of peptide drugs, such as human parathyroid hormone hPTH(1-34), human ghrelin and human motilin, through the mucosa of small intestine, lung, nasal cavity and other mucosa. Also, unlike any of the conventional mucosal absorption-enhancers, the composition for mucosal administration of the present invention does not cause tissue damage and is therefore highly safe for use.
摘要:
To provide a therapeutic agent for gastrointestinal disorder such as diabetic gastroparesis. A postprandial gastrokinetic agent containing (A) ghrelin or a ghrelin agonist and (B) motilin or a motilin agonist as active ingredients, in which both the ingredients (A) and (B) are administered so as to act on the stomach after food intake.